유럽의 오가노이드 시장 보고서(2021-2031년) : 범위, 부문, 역학, 경쟁 분석

The Europe organoids market is projected to grow significantly, reaching approximately US$ 5,016.03 million by 2031, up from US$ 1,018.12 million in 2023, reflecting a compound annual growth rate (CAGR) of 22.1% during this period.

Executive Summary and Market Analysis

The organoids market in Europe is divided into several regions, including Germany, France, Italy, the UK, Spain, and the Rest of Europe. The growth of this market is driven by several factors, including the increasing demand for tissue engineering and organ transplantation, the rising use of organoids in disease modeling, gene mutation studies, and tumor modeling, as well as heightened research activities related to organoids. Additionally, the influx of funding and investments from both public and private sectors is expected to create promising opportunities for market expansion in the coming years.

Market Segmentation Analysis

The Europe organoids market can be analyzed through various segments, including type, application, source, offering, and method:

• Type: The market is categorized into organoids derived from the intestine, liver, stomach, pancreas, lung, brain, kidney, and others. In 2023, the intestine organoids held the largest market share.
• Application: The applications of organoids include developmental biology, infectious disease pathology, regenerative medicine, drug toxicity and efficacy testing, drug discovery, and personalized medicine. Developmental biology applications dominated the market in 2023.
• Source: The market is divided into organoids sourced from pluripotent stem cells and organ-specific adult stem cells, with pluripotent stem cells holding a larger market share in 2023.
• Offering: This segment includes instruments, consumables, and services, with consumables leading the market in 2023. Instruments are further divided into devices and equipment, while consumables include sensors and other items.
• Method: The methods used in organoid production include micropatterned plates, ultralow attachment plates, hanging drop, microdroplet or emulsion techniques, with the hanging drop method being the most prevalent in 2023.

Market Outlook

The demand for innovative drugs is accelerating the pace of drug discovery and research. As of 2021, there were approximately 384,288 clinical trial studies registered on ClinicalTrials.gov. A survey by HUB indicates that organoids can enhance the cost-effectiveness of expensive drugs by identifying patients unlikely to benefit from certain treatments, thus optimizing clinical trial designs. Organoids are not only utilized in cancer research but also in studies related to cystic fibrosis, polycystic kidney disease, microcephaly, and infections affecting the gut and airways. They can replicate organ properties, including structure and function, and can restore the genetic and epigenetic states of tissues, making them suitable for gene editing applications.

Recent studies have shown promising results in combining CRISPR-Cas9 technology with organoids, leading to advancements in treatments for conditions like cystic fibrosis. For example, a 2020 study highlighted a biobank of cystic fibrosis intestinal organoids from 664 patients, with a significant portion potentially benefiting from gene editing. However, challenges remain regarding the efficiency and success rates of gene-edited organoids, necessitating further research into their safety, stability, and functionality. The ongoing focus on drug discovery in previously unexplored medical areas presents substantial growth opportunities for the organoids market.

Country Insights

The Europe organoids market is further analyzed by country, with Germany leading the market in 2023. Germany is recognized for its robust biotechnology sector, characterized by high-quality products and the presence of major biotechnology firms. For instance, researchers at the Max Planck Institute for Molecular Biomedicine in Munster have made strides in automating the production of midbrain organoids, enhancing the potential for large-scale research and high-throughput drug discovery.

The demand for tissue engineering and organ transplantation in Germany is expected to drive market growth, as there is a significant gap between organ supply and demand. In 2021, only 2,905 organs were donated, while the demand on the transplant list reached 8,730. Human organoids are increasingly being used to study diseases and have the potential to serve as transplantable organs, mitigating issues related to tissue rejection and the risk of introducing animal pathogens.

Company Profiles

Key players in the organoids market include STEMCELL Technologies Inc., Molecular Devices, Hubrecht Organoid Technology, Definigen, Organoid Therapeutics, Thermo Fisher Scientific, Corning, Merck KGaA, InSphero, ACRO Biosystems, Bio-Techne, SUN bioscience, ORGANOID SCIENCES, Crown Bioscience, Sartorius AG, 3D Biotek, Prellis Biologics, 3Dnamics, and Cellesce. These companies are pursuing various strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence and offer innovative solutions.

Table Of Contents

1. Introduction

• 1.1 Report Guidance
• 1.2 Market Segmentation

2. Executive Summary

• 2.1 Key Insights

3. Research Methodology

• 3.1 Secondary Research
• 3.2 Primary Research
  • 3.2.1 Hypothesis formulation:
  • 3.2.2 Macro-economic factor analysis:
  • 3.2.3 Developing base number:
  • 3.2.4 Data Triangulation:
  • 3.2.5 Country level data:

4. Europe Organoids Market - Key Market Dynamics

• 4.1 Market Drivers
  • 4.1.1 Increasing Demand for Tumor Modeling and Biobanking
  • 4.1.2 Surging Adoption of Personalized Drugs
• 4.2 Market Restraints
  • 4.2.1 Dearth of Skilled Professionals
• 4.3 Market Opportunities
  • 4.3.1 Focus on Drug Discovery Activities
• 4.4 Future Trends
  • 4.4.1 Combination of Organoids and Organ-on-a-Chip
• 4.5 Impact of Drivers and Restraints:

5. Organoids Market - Europe Analysis

• 5.1 Europe Organoids Market Revenue (US$ Million), 2021-2031
• 5.2 Europe Organoids Market Forecast Analysis

6. Europe Organoids Market Analysis - by Type

• 6.1 Intestine
  • 6.1.1 Overview
  • 6.1.2 Intestine: Europe Organoids Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 6.2 Liver
  • 6.2.1 Overview
  • 6.2.2 Liver: Europe Organoids Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 6.3 Stomach
  • 6.3.1 Overview
  • 6.3.2 Stomach: Europe Organoids Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 6.4 Pancreas
  • 6.4.1 Overview
  • 6.4.2 Pancreas: Europe Organoids Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 6.5 Lung
  • 6.5.1 Overview
  • 6.5.2 Lung: Europe Organoids Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 6.6 Brain
  • 6.6.1 Overview
  • 6.6.2 Brain: Europe Organoids Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 6.7 Kidney
  • 6.7.1 Overview
  • 6.7.2 Kidney: Europe Organoids Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 6.8 Others
  • 6.8.1 Overview
  • 6.8.2 Others: Europe Organoids Market - Revenue and Forecast, 2021-2031 (US$ Million)

7. Europe Organoids Market Analysis - by Application

• 7.1 Developmental Biology Disease
  • 7.1.1 Overview
  • 7.1.2 Developmental Biology Disease: Europe Organoids Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 7.2 Pathology of Infectious Disease
  • 7.2.1 Overview
  • 7.2.2 Pathology of Infectious Disease: Europe Organoids Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 7.3 Regenerative Medicine
  • 7.3.1 Overview
  • 7.3.2 Regenerative Medicine: Europe Organoids Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 7.4 Drug Toxicity and Efficacy Testing
  • 7.4.1 Overview
  • 7.4.2 Drug Toxicity and Efficacy Testing: Europe Organoids Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 7.5 Drug Discovery and Personalized Medicine
  • 7.5.1 Overview
  • 7.5.2 Drug Discovery and Personalized Medicine: Europe Organoids Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 7.6 Others
  • 7.6.1 Overview
  • 7.6.2 Others: Europe Organoids Market - Revenue and Forecast, 2021-2031 (US$ Million)

8. Europe Organoids Market Analysis - by Source

• 8.1 Pluripotent Stem Cells
  • 8.1.1 Overview
  • 8.1.2 Pluripotent Stem Cells: Europe Organoids Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 8.2 Organ-Specific Adult Stem Cell
  • 8.2.1 Overview
  • 8.2.2 Organ-Specific Adult Stem Cell: Europe Organoids Market - Revenue and Forecast, 2021-2031 (US$ Million)

9. Europe Organoids Market Analysis - by Offering

• 9.1 Instruments
  • 9.1.1 Overview
  • 9.1.2 Instruments: Europe Organoids Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 9.2 Consumables
  • 9.2.1 Overview
  • 9.2.2 Consumables: Europe Organoids Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 9.3 Services
  • 9.3.1 Overview
  • 9.3.2 Services: Europe Organoids Market - Revenue and Forecast, 2021-2031 (US$ Million)

10. Europe Organoids Market Analysis - by Method

• 10.1 Micropatterned Plates
  • 10.1.1 Overview
  • 10.1.2 Micropatterned Plates: Europe Organoids Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 10.2 Ultralow Attachment Plates
  • 10.2.1 Overview
  • 10.2.2 Ultralow Attachment Plates: Europe Organoids Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 10.3 Hanging Drop
  • 10.3.1 Overview
  • 10.3.2 Hanging Drop: Europe Organoids Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 10.4 Microdroplet or Emulsion
  • 10.4.1 Overview
  • 10.4.2 Microdroplet or Emulsion: Europe Organoids Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 10.5 Others
  • 10.5.1 Overview
  • 10.5.2 Others: Europe Organoids Market - Revenue and Forecast, 2021-2031 (US$ Million)

11. Europe Organoids Market - Country Analysis

• 11.1 Europe
  • 11.1.1 Europe Organoids Market - Revenue and Forecast Analysis - by Country
    • 11.1.1.1 Europe Organoids Market - Revenue and Forecast Analysis - by Country
    • 11.1.1.2 Germany: Europe Organoids Market - Revenue and Forecast, 2021-2031 (US$ Million)
      • 11.1.1.2.1 Germany: Europe Organoids Market Share - by Type
      • 11.1.1.2.2 Germany: Europe Organoids Market Share - by Application
      • 11.1.1.2.3 Germany: Europe Organoids Market Share - by Source
      • 11.1.1.2.4 Germany: Europe Organoids Market Share - by Offering
      • 11.1.1.2.5 Germany: Europe Organoids Market Share - by Instruments
      • 11.1.1.2.6 Germany: Europe Organoids Market Share - by Consumables
      • 11.1.1.2.7 Germany: Europe Organoids Market Share - by Method
    • 11.1.1.3 France: Europe Organoids Market - Revenue and Forecast, 2021-2031 (US$ Million)
      • 11.1.1.3.1 France: Europe Organoids Market Share - by Type
      • 11.1.1.3.2 France: Europe Organoids Market Share - by Application
      • 11.1.1.3.3 France: Europe Organoids Market Share - by Source
      • 11.1.1.3.4 France: Europe Organoids Market Share - by Offering
      • 11.1.1.3.5 France: Europe Organoids Market Share - by Instruments
      • 11.1.1.3.6 France: Europe Organoids Market Share - by Consumables
      • 11.1.1.3.7 France: Europe Organoids Market Share - by Method
    • 11.1.1.4 United Kingdom: Europe Organoids Market - Revenue and Forecast, 2021-2031 (US$ Million)
      • 11.1.1.4.1 United Kingdom: Europe Organoids Market Share - by Type
      • 11.1.1.4.2 United Kingdom: Europe Organoids Market Share - by Application
      • 11.1.1.4.3 United Kingdom: Europe Organoids Market Share - by Source
      • 11.1.1.4.4 United Kingdom: Europe Organoids Market Share - by Offering
      • 11.1.1.4.5 United Kingdom: Europe Organoids Market Share - by Instruments
      • 11.1.1.4.6 United Kingdom: Europe Organoids Market Share - by Consumables
      • 11.1.1.4.7 United Kingdom: Europe Organoids Market Share - by Method
    • 11.1.1.5 Italy: Europe Organoids Market - Revenue and Forecast, 2021-2031 (US$ Million)
      • 11.1.1.5.1 Italy: Europe Organoids Market Share - by Type
      • 11.1.1.5.2 Italy: Europe Organoids Market Share - by Application
      • 11.1.1.5.3 Italy: Europe Organoids Market Share - by Source
      • 11.1.1.5.4 Italy: Europe Organoids Market Share - by Offering
      • 11.1.1.5.5 Italy: Europe Organoids Market Share - by Instruments
      • 11.1.1.5.6 Italy: Europe Organoids Market Share - by Consumables
      • 11.1.1.5.7 Italy: Europe Organoids Market Share - by Method
    • 11.1.1.6 Spain: Europe Organoids Market - Revenue and Forecast, 2021-2031 (US$ Million)
      • 11.1.1.6.1 Spain: Europe Organoids Market Share - by Type
      • 11.1.1.6.2 Spain: Europe Organoids Market Share - by Application
      • 11.1.1.6.3 Spain: Europe Organoids Market Share - by Source
      • 11.1.1.6.4 Spain: Europe Organoids Market Share - by Offering
      • 11.1.1.6.5 Spain: Europe Organoids Market Share - by Instruments
      • 11.1.1.6.6 Spain: Europe Organoids Market Share - by Consumables
      • 11.1.1.6.7 Spain: Europe Organoids Market Share - by Method
    • 11.1.1.7 Rest of Europe: Europe Organoids Market - Revenue and Forecast, 2021-2031 (US$ Million)
      • 11.1.1.7.1 Rest of Europe: Europe Organoids Market Share - by Type
      • 11.1.1.7.2 Rest of Europe: Europe Organoids Market Share - by Application
      • 11.1.1.7.3 Rest of Europe: Europe Organoids Market Share - by Source
      • 11.1.1.7.4 Rest of Europe: Europe Organoids Market Share - by Offering
      • 11.1.1.7.5 Rest of Europe: Europe Organoids Market Share - by Instruments
      • 11.1.1.7.6 Rest of Europe: Europe Organoids Market Share - by Consumables
      • 11.1.1.7.7 Rest of Europe: Europe Organoids Market Share - by Method

12. Industry Landscape

• 12.1 Overview
• 12.2 Growth Strategies in Organoids Market
• 12.3 Organic Growth Strategies
  • 12.3.1 Overview
• 12.4 Inorganic Growth Strategies
  • 12.4.1 Overview

13. Company Profiles

• 13.1 STEMCELL Technologies Inc
  • 13.1.1 Key Facts
  • 13.1.2 Business Description
  • 13.1.3 Products and Services
  • 13.1.4 Financial Overview
  • 13.1.5 SWOT Analysis
  • 13.1.6 Key Developments
• 13.2 Molecular Devices, LLC.
  • 13.2.1 Key Facts
  • 13.2.2 Business Description
  • 13.2.3 Products and Services
  • 13.2.4 Financial Overview
  • 13.2.5 SWOT Analysis
  • 13.2.6 Key Developments
• 13.3 Hubrecht Organoid Technology
  • 13.3.1 Key Facts
  • 13.3.2 Business Description
  • 13.3.3 Products and Services
  • 13.3.4 Financial Overview
  • 13.3.5 SWOT Analysis
  • 13.3.6 Key Developments
• 13.4 Definigen
  • 13.4.1 Key Facts
  • 13.4.2 Business Description
  • 13.4.3 Products and Services
  • 13.4.4 Financial Overview
  • 13.4.5 SWOT Analysis
  • 13.4.6 Key Developments
• 13.5 Organoid Therapeutics
  • 13.5.1 Key Facts
  • 13.5.2 Business Description
  • 13.5.3 Products and Services
  • 13.5.4 Financial Overview
  • 13.5.5 SWOT Analysis
  • 13.5.6 Key Developments
• 13.6 Thermo Fisher Scientific Inc
  • 13.6.1 Key Facts
  • 13.6.2 Business Description
  • 13.6.3 Products and Services
  • 13.6.4 Financial Overview
  • 13.6.5 SWOT Analysis
  • 13.6.6 Key Developments
• 13.7 Corning Inc
  • 13.7.1 Key Facts
  • 13.7.2 Business Description
  • 13.7.3 Products and Services
  • 13.7.4 Financial Overview
  • 13.7.5 SWOT Analysis
  • 13.7.6 Key Developments
• 13.8 Merck KGaA
  • 13.8.1 Key Facts
  • 13.8.2 Business Description
  • 13.8.3 Products and Services
  • 13.8.4 Financial Overview
  • 13.8.5 SWOT Analysis
  • 13.8.6 Key Developments
• 13.9 InSphero
  • 13.9.1 Key Facts
  • 13.9.2 Business Description
  • 13.9.3 Products and Services
  • 13.9.4 Financial Overview
  • 13.9.5 SWOT Analysis
  • 13.9.6 Key Developments
• 13.10 ACRO Biosystems.
  • 13.10.1 Key Facts
  • 13.10.2 Business Description
  • 13.10.3 Products and Services
  • 13.10.4 Financial Overview
  • 13.10.5 SWOT Analysis
  • 13.10.6 Key Developments
• 13.11 Bio-Techne Corp
  • 13.11.1 Key Facts
  • 13.11.2 Business Description
  • 13.11.3 Products and Services
  • 13.11.4 Financial Overview
  • 13.11.5 SWOT Analysis
  • 13.11.6 Key Developments
• 13.12 SUN bioscience SA
  • 13.12.1 Key Facts
  • 13.12.2 Business Description
  • 13.12.3 Products and Services
  • 13.12.4 Financial Overview
  • 13.12.5 SWOT Analysis
  • 13.12.6 Key Developments
• 13.13 ORGANOID SCIENCES Co., Ltd.
  • 13.13.1 Key Facts
  • 13.13.2 Business Description
  • 13.13.3 Products and Services
  • 13.13.4 Financial Overview
  • 13.13.5 SWOT Analysis
  • 13.13.6 Key Developments
• 13.14 Crown Bioscience Inc
  • 13.14.1 Key Facts
  • 13.14.2 Business Description
  • 13.14.3 Products and Services
  • 13.14.4 Financial Overview
  • 13.14.5 SWOT Analysis
  • 13.14.6 Key Developments
• 13.15 Sartorius AG
  • 13.15.1 Key Facts
  • 13.15.2 Business Description
  • 13.15.3 Products and Services
  • 13.15.4 Financial Overview
  • 13.15.5 SWOT Analysis
  • 13.15.6 Key Developments
• 13.16 3D Biotek LLC
  • 13.16.1 Key Facts
  • 13.16.2 Business Description
  • 13.16.3 Products and Services
  • 13.16.4 Financial Overview
  • 13.16.5 SWOT Analysis
  • 13.16.6 Key Developments
• 13.17 Prellis Biologics Inc.
  • 13.17.1 Key Facts
  • 13.17.2 Business Description
  • 13.17.3 Products and Services
  • 13.17.4 Financial Overview
  • 13.17.5 SWOT Analysis
  • 13.17.6 Key Developments
• 13.18 3Dnamics Inc.
  • 13.18.1 Key Facts
  • 13.18.2 Business Description
  • 13.18.3 Products and Services
  • 13.18.4 Financial Overview
  • 13.18.5 SWOT Analysis
  • 13.18.6 Key Developments
• 13.19 Cellesce Ltd
  • 13.19.1 Key Facts
  • 13.19.2 Business Description
  • 13.19.3 Products and Services
  • 13.19.4 Financial Overview
  • 13.19.5 SWOT Analysis
  • 13.19.6 Key Developments

14. Appendix

• 14.1 About The Insight Partners